Health minister Mark Butler confirms Ocrevus, Kesimpta and Lemtrada will stay subsidised amid questions about the Pharmaceutical Benefits SchemeGet our breaking news email, free app or daily news podcastAustralians living with multiple sclerosis will continue receiving cheaper access to life-changing medical treatments, after an expert advisory panel decided to maintain taxpayer subsidies for key drugs.The health minister, Mark Butler, confirmed on Thursday that the drugs – Ocrevus, Kesimpta and Lemtrada – would not be removed from the Pharmaceutical Benefits Scheme, ending uncertainty sparked by their manufacturers, which were pushing the government to pay more. Continue reading...
Source: The Guardian Australia
